Thrombosis and Thrombocytopenia Syndrome Causing Isolated Symptomatic Carotid Occlusion after Covid-19 Vaccine

• References

• 1 Centers for Disease Control and Prevention. Selected Adverse Events Reported after COVID-19 Vaccination. Accessed September 9, 2021 at: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/adverse-events.html
• 2 MHRA - Medicines & Healthcare products Regulatory Agency. Coronavirus vaccine - weekly summary of Yellow Card reporting. Accessed September 9, 2021 at: https://www.gov.uk/government/publications/coronavirus-covid-19-vaccine-adversereactions/coronavirus-vaccine-summary-of-yellow-card-reporting#yellow-card-reports
• 3 European Medicines Agency. COVID-19 vaccine safety update. Accessed September 9, 2021 at: https://www.ema.europa.eu/en/human-regulatory/overview/public-healththreats/coronavirus-disease-covid-19/treatments-vaccines/vaccines-covid-19/covid-19-vaccines-authorised#safety-updates-for-authorised-covid-19-vaccines-section
• 4 Chen RT, Black S. Updated Proposed Brighton Collaboration process for developing a standard case definition for study of new clinical syndrome X, as applied to Thrombosis with Thrombocytopenia Syndrome (TTS). Accessed September 9, 2021 at: https://brightoncollaboration.us/wp-content/uploads/2021/05/TTS-Interim-CaseDefinition-v10.16.3-May-23-2021.pdf
• 5 MacNeil JR, Su JR, Broder KR. et al. Updated recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen (Johnson & Johnson) COVID-19 vaccine after reports of thrombosis with thrombocytopenia syndrome among vaccine recipients - United States, April 2021. Morb Mortal Wkly Rep 2021; 70 (17) 651-656
• 6 World Health Organization. Guidance for clinical case management of thrombosis with thrombocytopenia syndrome (TTS) following vaccination to prevent coronavirus disease (COVID-19). Accessed September 9, 2021 at: https://www.who.int/publications-detail-redirect/WHO-2019-nCoV-TTS-2021.1
• 7 Cines DB, Bussel JB. SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia. N Engl J Med 2021; 384 (23) 2254-2256
• 8 Hursting MJ, Pai PJ, McCracken JE. et al. Platelet factor 4/heparin antibodies in blood bank donors. Am J Clin Pathol 2010; 134 (05) 774-780
• 9 Schultz NH, Sørvoll IH, Michelsen AE. et al. Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination. N Engl J Med 2021; 384 (22) 2124-2130
• 10 Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med 2021; 384 (22) 2092-2101
• 11 Sánchez van Kammen M, Heldner MR, Brodard J. et al. Frequency of thrombocytopenia and platelet factor 4/heparin antibodies in patients with cerebral venous sinus thrombosis prior to the COVID-19 pandemic. JAMA 2021; 326 (04) 332-338
• 12 Platton S, Bartlett A, MacCallum P. et al. Evaluation of laboratory assays for anti-platelet factor 4 antibodies after ChAdOx1 nCOV-19 vaccination. J Thromb Haemost 2021; 19 (08) 2007-2013
• 13 Kenda J, Lovrič D, Škerget M, Milivojević N. Treatment of ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia related acute ischemic stroke. J Stroke Cerebrovasc Dis 2021; 30 (11) 106072
• 14 Gabarin N, Patterson S, Pai M. et al. Venous thromboembolism and mild thrombocytopenia after ChAdOx1 nCoV-19 vaccination. Thromb Haemost 2021;
• 15 Charidimou A, Samudrala S, Cervantes-Arslanian AM, Sloan JM, Dasenbrock HH, Daneshmand A. Vaccine-induced immune thrombotic thrombocytopenia with concurrent arterial and venous thrombi following Ad26.COV2.S vaccination. J Stroke Cerebrovasc Dis 2021; 30 (12) 106113
• 16 Scully M, Singh D, Lown R. et al. Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination. N Engl J Med 2021; 384 (23) 2202-2211
• 17 Costentin G, Ozkul-Wermester O, Triquenot A. et al. Acute ischemic stroke revealing ChAdOx1 nCov-19 vaccine-induced immune thrombotic thrombocytopenia: impact on recanalization strategy. J Stroke Cerebrovasc Dis 2021; 30 (09) 105942
• 18 De Michele M, Iacobucci M, Chistolini A. et al. Malignant cerebral infarction after ChAdOx1 nCov-19 vaccination: a catastrophic variant of vaccine-induced immune thrombotic thrombocytopenia. Nat Commun 2021; 12 (01) 4663
• 19 Bayas A, Menacher M, Christ M, Behrens L, Rank A, Naumann M. Bilateral superior ophthalmic vein thrombosis, ischaemic stroke, and immune thrombocytopenia after ChAdOx1 nCoV-19 vaccination. Lancet 2021; 397 (10285): e11
• 20 Blauenfeldt RA, Kristensen SR, Ernstsen SL, Kristensen CCH, Simonsen CZ, Hvas AM. Thrombocytopenia with acute ischemic stroke and bleeding in a patient newly vaccinated with an adenoviral vector-based COVID-19 vaccine. J Thromb Haemost 2021; 19 (07) 1771-1775
• 21 Sachs UJ, Cooper N, Czwalinna A. et al. PF4-dependent immunoassays in patients with vaccine-induced immune thrombotic thrombocytopenia: results of an interlaboratory comparison. Thromb Haemost 2021;
• 22 Walter U, Fuchs M, Grossmann A. et al. Adenovirus-vectored COVID-19 vaccine-induced immune thrombosis of carotid artery: a case report. Neurology 2021
• 23 Pavord S, Scully M, Hunt BJ. et al. Clinical features of vaccine-induced immune thrombocytopenia and thrombosis. N Engl J Med 2021; 385: 1680-1689
• 24 Fridman S, Lownie SP, Mandzia J. Diagnosis and management of carotid free-floating thrombus: a systematic literature review. Int J Stroke 2019; 14 (03) 247-256
• 25 Zazzeron L, Rosovsky RP, Bittner EA, Chang MG. Comparison of published guidelines for the diagnosis and the management of vaccine-induced immune thrombotic thrombocytopenia. Crit Care Explor 2021; 3 (09) e0519